Pricing Log in Create free account

Apimeds Pharmaceuticals US, Inc. (APUS) vs Sonoma Pharmaceuticals, Inc. (SNOA)

Apimeds Pharmaceuticals US, Inc. and Sonoma Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Sonoma Pharmaceuticals, Inc. is the larger, with a market value of $5.1M against $4.1M — 1.2× the size. Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −10.3%) and the higher return on invested capital (−16.0% vs −70.0%). Across the 13 metrics below, Sonoma Pharmaceuticals, Inc. leads on 7 and Apimeds Pharmaceuticals US, Inc. on 6.

Valuation

Metric APUS SNOA Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S n/m 0.19 2.08
P/B 0.04 0.63 1.79
Price to free cash flow n/m n/m 16.29
EV/EBITDA n/m 0.86 12.22
EV/Sales n/m (0.05) 2.87
Earnings yield (1,394.72%) (112.96%) (15.94%)
Free cash flow yield (295.94%) (63.92%) 0.00%

Profitability

Metric APUS SNOA Drug Manufacturers Specialty & Generic median
Gross margin — 38.91% 53.51%
Operating margin 0.00% (6.41%) 0.00%
Net margin 0.00% (10.33%) (2.45%)
Free cash flow margin 0.00% (12.11%) 0.00%
Return on equity (100.13%) (42.52%) (0.80%)
Return on assets (84.20%) (13.85%) (1.67%)
Return on invested capital (15.96%) (69.96%) 0.00%

Growth

Metric APUS SNOA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 47.00% 5.22%
EPS growth (last fiscal year) (205.56%) 32.26% 42.91%
Revenue growth, 5-year CAGR — 0.95% 7.24%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS SNOA Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 0.00 0.04
Current ratio 0.51 2.99 2.41
Net debt to EBITDA 0.38 1.03 1.01

Dividend

Metric APUS SNOA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric APUS SNOA Drug Manufacturers Specialty & Generic median
Market cap 4.12m 5.13m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack